TTrialPathMatch Me to Trials
← Back to trials
RecruitingMetabolic Dysfunction-Associated Steatotic Liver DiseaseMASLD

Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Eligible age

18–75 yrs

Accepts

All genders

Locations

3 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This study will test a Regeneron study drug called ALN-CIDEB to find out whether it may help treat a liver disease called metabolic dysfunction-associated steatohepatitis (MASH). MASH is more advanced stage of a broader liver disease, MASLD. MASLD is a liver condition caused by too much fat building up in the liver. This can lead to liver scarring and inflammation and can reduce the liver's ability to keep the body healthy. Cell death-inducing DFFA-like effector B (CIDEB) is a protein made by liver cells that helps the liver to store fat. The study is looking at: * What side effects ALN-CIDEB might cause * How well ALN-CIDEB works to change liver fat, liver injury, and liver scarring * How ALN-CIDEB could affect the body and the liver, which can help researchers understand why ALN-CIDEB works better for some people than others

Sponsor: Regeneron Pharmaceuticals

Where it's recruiting

Florida

Miami

Louisiana

Marrero · Metairie

Texas

Georgetown

Source: ClinicalTrials.gov · NCT07854782 · last updated 2026-11-17